39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 39,241 shares of the company’s stock, valued at approximately $705,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. KBC Group NV acquired a new position in shares of Amylyx Pharmaceuticals during the first quarter valued at about $26,000. Meeder Asset Management Inc. purchased a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Amylyx Pharmaceuticals by 954.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after purchasing an additional 3,493 shares during the last quarter. California State Teachers Retirement System acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth about $28,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Amylyx Pharmaceuticals by 54.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock worth $64,000 after buying an additional 1,890 shares during the period. Institutional investors own 95.84% of the company’s stock.

Insider Activity at Amylyx Pharmaceuticals

In related news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the transaction, the insider directly owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.90% of the company’s stock.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX stock traded up $0.23 on Thursday, reaching $38.83. 3,571,107 shares of the company were exchanged, compared to its average volume of 1,607,203. Amylyx Pharmaceuticals, Inc. has a 1 year low of $7.96 and a 1 year high of $39.93. The business has a 50-day moving average price of $19.38 and a 200 day moving average price of $16.35. The company has a market cap of $4.33 billion, a price-to-earnings ratio of -27.15 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). As a group, equities analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Guggenheim upped their price objective on shares of Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday. Mizuho increased their price target on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday. Wolfe Research upgraded shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday. Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, HC Wainwright increased their price target on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $36.25.

Amylyx Pharmaceuticals News Summary

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Avexitide achieved the primary endpoint in the Phase 3 LUCIDITY trial for post-bariatric hypoglycemia, reducing hypoglycemic events by 55%. The result strengthens the case for an FDA filing by the end of 2026 and improves the drug’s potential commercial value. AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
• Positive Sentiment: Analysts raised their outlook for Amylyx. HC Wainwright maintained a Buy rating and a $55 price target while increasing its EPS forecasts to $3.22 for 2029 and $6.40 for 2030, reflecting expectations for successful commercialization and substantially higher future revenue. HC Wainwright Raises Amylyx Price Target
• Positive Sentiment: Guggenheim raised its price target to $55 from $40 with a Buy rating, while Robert W. Baird increased its target to $52 from $28 and assigned an Outperform rating. Wolfe Research also upgraded the shares to Strong Buy, adding to the positive analyst momentum.
• Neutral Sentiment: The clinical success has pushed AMLX toward regulatory and commercial execution milestones. Investors will now focus on additional LUCIDITY data, the FDA filing, approval prospects and Amylyx’s ability to establish avexitide commercially.
• Negative Sentiment: Amylyx priced an upsized public offering of 14.09 million shares at $35.50 per share, expected to raise approximately $500 million before expenses. Underwriters may purchase another 2.11 million shares, creating potential dilution and adding supply near the offering price. Amylyx Prices Upsized $500 Million Offering

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on therapies intended to protect nerve cells and address the underlying biology of conditions such as amyotrophic lateral sclerosis (ALS) and other serious neurological disorders.

Amylyx’s lead product, AMX0035, was marketed in the United States as Relyvrio and in Canada as Albrioza for the treatment of ALS. Following results from a confirmatory clinical trial that did not meet its objectives, the company announced the voluntary withdrawal of the product from the market in 2024.